An Endocannabinoid-Boosting Drug Enhanced Morphine's Pain Relief Without the Side Effects
Combining a MAGL inhibitor (which boosts the endocannabinoid 2-AG) with morphine produced synergistic pain relief in a neuropathic pain model without the constipation, tolerance, or cannabis-like side effects of either drug alone.
Quick Facts
What This Study Found
Researchers combined morphine with MJN110, a selective MAGL inhibitor that boosts 2-AG levels, in a mouse model of neuropathic pain (chronic constriction injury).
When used alone, both drugs reduced pain in a dose-dependent manner. When combined at low doses, the effect was synergistic (better than additive), meaning significantly lower doses of each drug produced full pain relief.
The combination produced pain relief through mu-opioid, CB1, and CB2 receptors simultaneously. Critically, the combination avoided three major side effects: it did not reduce gastric motility (no constipation), did not produce cannabis-like subjective effects (drug discrimination test), and when given repeatedly for 6 days, showed no evidence of tolerance development.
This is significant because opioid tolerance, constipation, and addiction are the primary clinical limitations of opioid pain treatment.
Key Numbers
Morphine ED50: 2.4 mg/kg. MJN110 ED50: 0.43 mg/kg. Combination: synergistic (isobolographic analysis). 6 days of twice-daily combination dosing: no tolerance. No reduction in gastric motility. No cannabimimetic effects in drug discrimination. Required mu-opioid, CB1, and CB2 receptors.
How They Did This
Mouse chronic constriction injury model of neuropathic pain. Dose-response curves generated for morphine and MJN110 separately. Isobolographic analysis determined synergistic, additive, or antagonistic interactions. Receptor involvement confirmed with selective antagonists for mu-opioid, CB1, and CB2 receptors. Side effect testing included gastric motility, drug discrimination (cannabimimetic effects), and 6-day repeated dosing for tolerance assessment.
Why This Research Matters
The opioid epidemic has highlighted the urgent need for alternative or opioid-sparing pain treatments. This study shows that boosting the body's natural endocannabinoid system can dramatically reduce the amount of morphine needed for pain relief while avoiding the most dangerous opioid side effects, including tolerance that drives dose escalation.
The Bigger Picture
The endocannabinoid system and opioid system interact extensively. This study provides a practical demonstration of how this interaction can be exploited therapeutically: by boosting endocannabinoids alongside low-dose opioids, the therapeutic benefit is maintained while the addiction, tolerance, and side effect risks are dramatically reduced.
What This Study Doesn't Tell Us
Mouse study that needs human translation. The 6-day tolerance assessment is short. The neuropathic pain model (CCI) may not represent all chronic pain conditions. MJN110 is a research tool, not an approved drug. The drug discrimination test for cannabimimetic effects may not capture all subjective experiences relevant to humans.
Questions This Raises
- ?Would this opioid-sparing approach work in humans with chronic pain?
- ?Could MAGL inhibitors reduce opioid prescribing needs?
- ?Would the lack of tolerance persist beyond 6 days?
- ?Could this approach help people currently on high-dose opioids reduce their doses?
Trust & Context
- Key Stat:
- Endocannabinoid boost + morphine: synergistic pain relief with no constipation, no tolerance, no cannabis-like side effects.
- Evidence Grade:
- Moderate evidence from a comprehensive animal study with multiple validated outcome measures and control conditions.
- Study Age:
- Published in 2016. Opioid-sparing cannabinoid combinations remain an active area of preclinical and early clinical investigation.
- Original Title:
- The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 357(1), 145-56 (2016)
- Authors:
- Wilkerson, Jenny L(5), Niphakis, Micah J(7), Grim, Travis W(2), Mustafa, Mohammed A, Abdullah, Rehab A, Poklis, Justin L, Dewey, William L, Akbarali, Hamid, Banks, Matthew L, Wise, Laura E, Cravatt, Benjamin F, Lichtman, Aron H
- Database ID:
- RTHC-01304
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids reduce the need for opioid painkillers?
This animal study found that boosting the endocannabinoid 2-AG produced a synergistic interaction with morphine, meaning much lower doses of both were needed for full pain relief. The combination avoided constipation, tolerance, and psychoactive side effects.
How does this work?
The endocannabinoid and opioid systems both modulate pain but through different mechanisms. Activating both simultaneously produces better pain relief than either alone, allowing lower doses of each and reducing side effect risk. The effect required both cannabinoid (CB1, CB2) and opioid (mu) receptors.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-painkillers-opioid-interactions
- thc-and-muscle-relaxers-combining
- thc-and-ibuprofen-safe-combine-research
Cite This Study
https://rethinkthc.com/research/RTHC-01304APA
Wilkerson, Jenny L; Niphakis, Micah J; Grim, Travis W; Mustafa, Mohammed A; Abdullah, Rehab A; Poklis, Justin L; Dewey, William L; Akbarali, Hamid; Banks, Matthew L; Wise, Laura E; Cravatt, Benjamin F; Lichtman, Aron H. (2016). The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.. The Journal of pharmacology and experimental therapeutics, 357(1), 145-56. https://doi.org/10.1124/jpet.115.229971
MLA
Wilkerson, Jenny L, et al. "The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.." The Journal of pharmacology and experimental therapeutics, 2016. https://doi.org/10.1124/jpet.115.229971
RethinkTHC
RethinkTHC Research Database. "The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produ..." RTHC-01304. Retrieved from https://rethinkthc.com/research/wilkerson-2016-the-selective-monoacylglycerol-lipase
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.